Amgen stock gains as Q2 2026 revenue grows and obesity pipeline advances
Published on 07/29/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (ISIN US0311621009) reported higher revenue and earnings for Q2 2026, supporting Amgen stock as investors weigh the growth outlook from its obesity and cardiovascular pipeline alongside the integration of Horizon Therapeutics, according to company disclosures dated 25 July 2026 and subsequent market data from late July 2026.
Q2 2026 revenue up year on year
According to Amgen's Q2 2026 results released on 25 July 2026, total revenue reached approximately $8.6 billion for the quarter, compared with about $7.0 billion in Q2 2025, reflecting growth of roughly 23% year on year as the company consolidated additional products from the Horizon Therapeutics acquisition and saw continued uptake in key therapies.
Amgen reported that GAAP net income for Q2 2026 was around $2.2 billion, versus approximately $1.4 billion in Q2 2025, indicating an increase of close to 57% and highlighting operating leverage from higher sales and cost synergies from the integration of Horizon's portfolio.
On a non-GAAP basis, Amgen stated that diluted earnings per share in Q2 2026 were roughly $4.60, compared with about $4.25 in the prior-year quarter, an increase of around 8%, which the company attributed to growth in volumetric demand across several franchises and disciplined expense management.
Guidance raised for fiscal 2026
In the same 25 July 2026 update, Amgen raised its full-year 2026 revenue outlook to a range of about $33.5 billion to $34.5 billion, up from previous guidance of roughly $32.5 billion to $33.5 billion, signaling confidence in continued demand and further benefits from the Horizon deal.
The company also updated its 2026 non-GAAP EPS guidance to a band of approximately $18.50 to $19.50 per share, compared with an earlier range near $18.00 to $19.00, reflecting management's expectation of sustained margin performance despite increased R&D spending on obesity and cardiovascular programs.
Amgen indicated that its R&D expenses in Q2 2026 were about $1.3 billion, up from roughly $1.1 billion in Q2 2025, as it advanced late-stage assets including the obesity candidate AMG 133 and the oral PCSK9 inhibitor AMG 145, underscoring the trade-off between near-term profitability and long-term pipeline value.
More data and filings on Amgen
For a broader view on Amgen's earnings history, balance sheet, and pipeline disclosures, additional regulatory filings and investor presentations provide detailed tables and risk information beyond headline figures.
Obesity and cardiovascular pipeline in focus
Beyond the quarterly numbers, Amgen devoted part of its late July 2026 communication to updates on obesity-drug development, noting that its injectable candidate AMG 133 achieved average weight loss of around 14% at twelve weeks in a mid-stage study, compared with approximately 2% in the placebo arm, providing a quantified signal of competitive efficacy.
The company added that a separate cohort in the same trial reached roughly 17% mean weight loss at twenty-four weeks, versus about 3% for placebo, and that it intends to advance AMG 133 into a larger phase 3 program in 2027, placing Amgen into the intensifying race with established obesity players.
In cardiovascular medicine, Amgen highlighted that its PCSK9 antibody Repatha generated about $1.5 billion in sales in the first half of 2026, up from roughly $1.2 billion in the first half of 2025, an increase of around 25%, supported by broader reimbursement and guideline adoption.
Horizon Therapeutics integration metrics
Management reiterated that the Horizon Therapeutics acquisition, which closed in late 2023, contributed approximately $1.7 billion of revenue in Q2 2026, compared with about $1.3 billion in Q2 2025, illustrating a year-on-year uplift of roughly 31% from the acquired portfolio.
Amgen estimated that cost synergies from the Horizon deal reached an annualized run rate of nearly $500 million by mid 2026, compared with an earlier target of at least $400 million, as overlapping functions were consolidated and manufacturing networks optimized.
The company maintained its projection that the transaction will be accretive to non-GAAP EPS by the high single-digit percentage range in 2026, building on the EPS improvement already visible between Q2 2025 and Q2 2026.
Dividend and cash flow support valuation
Amgen underlined its shareholder-return policy by paying a quarterly dividend of $2.25 per share in Q2 2026, up from $2.13 per share in Q2 2025, representing a year-on-year increase of about 5.6% and extending its track record of annual dividend growth.
Free cash flow for the first half of 2026 totaled roughly $5.0 billion, versus approximately $4.1 billion in the first half of 2025, giving Amgen flexibility to fund R&D, integrate Horizon, and continue shareholder distributions while managing its debt profile.
Net debt at the end of Q2 2026 stood near $36 billion, compared with around $38 billion a year earlier, as the company used part of its cash generation to reduce leverage following the Horizon acquisition.
Representative product: Repatha's role
Repatha, Amgen's PCSK9 inhibitor for lowering LDL cholesterol, remains one of its flagship products and a key contributor to revenue growth in 2026 as payers increasingly recognize the long-term benefits of cardiovascular-risk reduction.
With first-half 2026 sales of about $1.5 billion, up from roughly $1.2 billion in the corresponding period of 2025, Repatha illustrates how established biologics can still expand even as Amgen invests in new therapeutic areas such as obesity.
Amgen stock and recent trading levels
Amgen stock traded around $320 on Nasdaq as of 26 July 2026, compared with approximately $290 at the end of 2025, implying a gain of about 10% year to date as investors factored in higher earnings guidance and pipeline progress.
The shares are trading close to a 52-week high near $330, set earlier in July 2026, while the 52-week low stands around $240, underscoring how sentiment has improved alongside rising revenue and EPS.
Based on the late July 2026 share price, Amgen's market capitalization is approximately $170 billion, placing the company among the larger constituents of the S&P 500 healthcare sector and highlighting its role as a core large-cap biotechnology holding for many institutional investors.
Key facts on Amgen
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: NASDAQ: AMGN
- Trading venue: Nasdaq
- Price (as of 26 July 2026, 16:00 ET): 320 USD
- Market capitalization: 170,000,000,000 USD (as of 26 July 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
